A well-controlled clinical study of Lenvatinib Plus Pembrolizumab in patients with Hepatocellular Carcinoma
Latest Information Update: 14 Jul 2020
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Merck & Co
- 14 Jul 2020 New trial record
- 08 Jul 2020 According to a Merck & Co media release, Since the CRL applications for KEYNOTE-524 study no longer meet the criteria for accelerated approval, both companies plan to work with the FDA to take appropriate next steps, which include conducting this well-controlled clinical trial that demonstrates substantial evidence of effectiveness and the clinical benefit of the combination.